Analysts’ Recent Ratings Updates for Chemed (CHE)

Chemed (NYSE: CHE) recently received a number of ratings updates from brokerages and research firms:

  • 5/9/2019 – Chemed was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Chemed exited first-quarter 2019 on a dull note. Earnings and revenues both missed the respective Zacks Consensus Estimate in the reported quarter. Unfavorable acuity mix shift, fluctuations in net room and board and contractual adjustments dented the top line during the quarter. On a positive note, Chemed witnessed solid revenue growth across key subsidiaries. Over the past few quarters, VITAS has been registering expanded average daily census. Meanwhile, the Roto-Rooter business has been seeing growth on strong performance by the core plumbing and drain cleaning service segments as well as solid growth in water restoration.”
  • 5/3/2019 – Chemed was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Chemed exited first-quarter 2019 on a dull note. Earnings and revenues both missed the respective Zacks Consensus Estimate in the reported quarter. Unfavorable acuity mix shift, fluctuations in net room and board and contractual adjustments dented the top line during the quarter. On a positive note, the company witnessed solid revenue growth across key subsidiaries. Chemed witnessed solid revenue growth across key subsidiaries. Over the past few quarters, VITAS has been registering expanded average daily census. Meanwhile, the Roto-Rooter business has been seeing growth on strong performance by the core plumbing and drain cleaning service segments as well as solid growth in water restoration.”
  • 5/1/2019 – Chemed was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 4/30/2019 – Chemed had its price target raised by analysts at Oppenheimer Holdings Inc. from $340.00 to $370.00. They now have an “outperform” rating on the stock.

Shares of Chemed stock opened at $329.33 on Wednesday. The company has a current ratio of 0.73, a quick ratio of 0.70 and a debt-to-equity ratio of 0.17. The firm has a market cap of $5.33 billion, a price-to-earnings ratio of 27.61, a P/E/G ratio of 2.97 and a beta of 1.18. Chemed Co. has a 12-month low of $260.03 and a 12-month high of $335.99.

Chemed (NYSE:CHE) last issued its quarterly earnings data on Monday, April 29th. The company reported $2.92 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.96 by ($0.04). The company had revenue of $462.03 million for the quarter, compared to analysts’ expectations of $468.28 million. Chemed had a net margin of 11.37% and a return on equity of 35.19%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.72 earnings per share. On average, analysts forecast that Chemed Co. will post 12.65 earnings per share for the current year.

In other Chemed news, CEO Kevin J. Mcnamara sold 5,000 shares of the business’s stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $323.47, for a total transaction of $1,617,350.00. Following the transaction, the chief executive officer now directly owns 155,094 shares of the company’s stock, valued at approximately $50,168,256.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director George J. Walsh III sold 646 shares of the business’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $326.83, for a total transaction of $211,132.18. Following the transaction, the director now directly owns 7,070 shares in the company, valued at $2,310,688.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,245 shares of company stock worth $6,955,533. Insiders own 3.96% of the company’s stock.

A number of institutional investors have recently modified their holdings of CHE. TimesSquare Capital Management LLC purchased a new position in Chemed during the 1st quarter valued at $54,316,000. Norges Bank purchased a new position in Chemed during the 4th quarter valued at $43,898,000. AJO LP increased its position in Chemed by 141.7% during the 1st quarter. AJO LP now owns 145,216 shares of the company’s stock valued at $46,479,000 after purchasing an additional 85,132 shares during the period. Northern Trust Corp increased its position in Chemed by 53.4% during the 1st quarter. Northern Trust Corp now owns 239,195 shares of the company’s stock valued at $76,560,000 after purchasing an additional 83,313 shares during the period. Finally, Ellis Investment Partners LLC purchased a new stake in shares of Chemed in the 1st quarter worth about $70,000. 87.79% of the stock is currently owned by institutional investors and hedge funds.

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.

Featured Story: Do stock splits help investors?

Receive News & Ratings for Chemed Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Co and related companies with MarketBeat.com's FREE daily email newsletter.